Quick Answer
RIGEL PHARMACEUTICALS INC reported Total Revenue of $294.28 million for fiscal year 2025.
RIGEL PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $294.28M +64.1% |
$179.28M +53.4% |
$116.88M -2.8% |
$120.24M -19.4% |
$149.24M +37.4% |
$108.62M +83.2% |
| Revenue (ASC 606) | $294.28M +64.1% |
$179.28M +53.4% |
$116.88M -2.8% |
$120.24M -19.4% |
$149.24M +37.4% |
$108.62M +83.2% |
| Net Income | $367.02M +1999.1% |
$17.48M +169.7% |
-$25.09M +57.2% |
-$58.57M -227.0% |
-$17.91M +39.8% |
-$29.74M +55.5% |
| Diluted EPS | $19.48 +1867.7% |
$0.99 +168.7% |
-$1.44 +58.1% |
-$3.44 -3027.3% |
-$0.11 +38.9% |
-$0.18 +55.0% |
| Total Assets | $513.59M +213.2% |
$163.98M +39.9% |
$117.22M -12.7% |
$134.28M -19.8% |
$167.33M +51.6% |
$110.38M -25.2% |
| Cash and Equivalents | $40.58M -28.5% |
$56.75M +73.1% |
$32.79M +34.0% |
$24.46M +29.5% |
$18.89M -37.8% |
$30.37M +34.9% |
| Stockholders Equity | $391.48M +11806.3% |
$3.29M +111.5% |
-$28.64M -110.4% |
-$13.62M -144.8% |
$30.37M -10.7% |
$34.03M -36.8% |
| R&D Expense | $33.30M +42.4% |
$23.38M -4.7% |
$24.52M | — | — | — |
| Operating Income | $125.47M +418.6% |
$24.19M +218.1% |
-$20.49M +63.1% |
-$55.55M -344.5% |
-$12.50M +56.9% |
-$28.97M +58.1% |
| Shares Outstanding | 18.31M +3.4% |
17.71M +1.3% |
17.48M -89.9% |
173.40M +1.0% |
171.60M +1.3% |
169.32M +0.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $69.46M | +25.6% | -31.7% |
| Revenue (ASC 606) | September 30, 2025 | $69.46M | +25.6% | -31.7% |
| Net Income | September 30, 2025 | $27.90M | +124.6% | -53.2% |
| Diluted EPS | September 30, 2025 | $1.46 | +108.6% | -55.5% |
| Total Assets | September 30, 2025 | $242.53M | +74.0% | +17.3% |
| Cash and Equivalents | September 30, 2025 | $48.53M | -6.1% | -9.1% |
| Stockholders Equity | September 30, 2025 | $117.61M | +903.6% | +43.5% |
| R&D Expense | June 30, 2011 | $17.11M | +1.7% | +1.7% |
| Operating Income | September 30, 2025 | $28.42M | +102.2% | -53.5% |
| Shares Outstanding | September 30, 2012 | 71.76M | +0.7% | +0.2% |
- RIGEL PHARMACEUTICALS INC reported Total Revenue of $294.28 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +64.1% in Total Revenue compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Revenue (ASC 606) of $294.28 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +64.1% in Revenue (ASC 606) compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Net Income of $367.02 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +1999.1% in Net Income compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Diluted EPS of $19.48 per share for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +1867.7% in Diluted EPS compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Total Assets of $513.59 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +213.2% in Total Assets compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Cash and Equivalents of $40.58 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed a decrease of -28.5% in Cash and Equivalents compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Stockholders Equity of $391.48 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +11806.3% in Stockholders Equity compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported R&D Expense of $33.30 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +42.4% in R&D Expense compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Operating Income of $125.47 million for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +418.6% in Operating Income compared to the prior fiscal year.
- RIGEL PHARMACEUTICALS INC reported Shares Outstanding of 18.31 million shares for fiscal year 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +3.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: